EMRIS PHARMA LTD

General Data

supplementary funding
Reg Number
516743176
Sector
Biomed
Established
2023
No. of Employees
5
Stage
R&D
Additional Funding
1

Description

Emris Pharma develops a topical medication to prevent skin toxicity in cancer patients receiving EGFR inhibitor treatment. Most Patients (80%-90%) treated with EGFR-inhibitor monoclonal antibodies (e.g. Cetuximab and Panitumumab) suffer from severe impair

Technology

Topical drug for the treatment of skin toxicities.

Targeted Customers

Skin Cancer Clinics.

Management personnel

Lyora Aharonov - CEO & Co-Founder
[email protected]
Ofra Benny - CTO & Co-Founder
[email protected]

Contact information

Name
Nizar Mishael
Email
[email protected]
Phone
0526551384
Country
Israel
Zip
1711102

Tags

BiotechnologyCancerLife SciencesMedTechPharmaceuticals

Classified Technologies

Biomedicine and pharmaceuticals

Winning details

Route name
Winning year

Technological Incubators 2020
Technological Incubators 2020
2024
Technological Incubators 2020
Technological Incubators 2020
2025
To the full list